The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol “ABBV”.
P/E ratio for AbbVie (ABBV)
P/E ratio as of May 2024 (TTM): 44.7
According to AbbVie's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 44.6524. At the end of 2022 the company had a P/E ratio of 24.3.
P/E ratio history for AbbVie from 2012 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 24.3 | 16.29% |
| 2021 | 20.9 | -43.89% |
| 2020 | 37.2 | 122.84% |
| 2019 | 16.7 | -35.26% |
| 2018 | 25.8 | -11.41% |
| 2017 | 29.1 | 70.28% |
| 2016 | 17.1 | -8.47% |
| 2015 | 18.7 | -68.3% |
| 2014 | 58.9 | 188.94% |
| 2013 | 20.4 | 92.03% |
| 2012 | 10.6 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 15.5 | -65.18% | 🇺🇸 USA |
 Eli Lilly LLY | 142 | 218.08% | 🇺🇸 USA |
 Amgen AMGN | 22.2 | -50.19% | 🇺🇸 USA |
 Biogen BIIB | 12.5 | -72.09% | 🇺🇸 USA |
 Gilead Sciences GILD | 15.5 | -65.38% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 11.1 | -75.12% | 🇺🇸 USA |
 AstraZeneca AZN | 38.8 | -13.08% | 🇬🇧 UK |
 GlaxoSmithKline GSK | 12.8 | -71.29% | 🇬🇧 UK |
 Neurocrine Biosciences
NBIX | 72.4 | 62.15% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.